Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial Academic Article uri icon

Overview

MeSH Major

  • CD8-Positive T-Lymphocytes
  • Chromatin
  • Neoplasms

abstract

  • Bristol-Myers Squibb.

publication date

  • November 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/S1470-2045(18)30700-9

PubMed ID

  • 30361170

Additional Document Info

start page

  • 1480

end page

  • 1492

volume

  • 19

number

  • 11